¿Aún no está registrado?

Cree su cuenta. Regístrese en Elsevier y obtendrá: información relevante, máxima actualización y promociones exclusivas.

Registrarme ahora
Ayuda - - Regístrese - Teléfono 902 888 740
Buscar en

Indexada en:



  • SCImago Journal Rank (SJR):0,11
  • Source Normalized Impact per Paper (SNIP):0,189
Hipertensión 2007;24:209-13 - DOI: 10.1016/S1889-1837(07)71702-6
Crecimiento ventricular izquierdo. Diagnóstico por electrocardiografía
Left ventricular growth. Diagnosis by electrocardiogram
B.M.W. Schmidt, R.E. Schmieder,
Departamento de Nefrología e Hipertensión. Universidad de Erlangen-Nürnberg. Erlangen. Alemania
Recibido 28 marzo 2007, Aceptado 10 abril 2007

Left ventricular hypertrophy is one of the main lesions of the target organs related with high blood pressure. This hypertrophy has an important effect on the cardiovascular prognosis of the hypertense patient.

The techniques used most to identify ventricular hypertrophy are the electrocardiogram and imaging methods. The primary advantages of the electrocardiogram are its generalized availability at a very low cost, its reproducibility and the observer independence. Its main weakness is its low sensitivity. The most widely used imaging method to evaluate left ventricular mass is the echocardiogram. However, the echocardiogram has a very large inter and intra-rater variability, commonly overestimates the ventricular mass in hypertrophied hearts and is largely based on geometric suppositions. Its main advantage is the possibility of evaluating ventricular filling and diastolic relaxation.

Left ventricular hypertrophy may be modified through the administration of antihypertensive drugs, the most effective ones being angiotensin receptor blockers and angiotensin converting enzyme inhibitors. Reduction of left ventricular mass is associated with a decrease of cardiovascular risk. Regression of hypertrophy should be defined as one of the goals of antihypertensive therapy, as an addition and independently to the control of blood pressure.

Palabras clave:
hipertrofia ventricular izquierda, electrocardiografía, terapia antihipertensiva
Key words:
left ventricular hypertrophy, electrocardiogram, antihypertensive therapy
El Texto completo solo está disponible en PDF
G. Schillaci,P. Verdecchia,C. Porcellati,O. Cuccurullo,C. Cosco,F. Perticone
Continuous Relation Between Left Ventricular Mass and Cardiovascular Risk in Essential Hypertension
Hipertensión, 35 (2000), pp. 580-586
D. Levy,M. Salomon,R.B. D'Agostino,A.J. Belanger,W.B. Kannel
Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy
Circulation, 90 (1994), pp. 1786-1793
W.B. Kannel,T. Gordon,W.P. Castelli,J.R. Margolis
Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study
Ann Intern Med, 72 (1970), pp. 813-822
D. Levy,R.J. Garrison,D.D. Savage,W.B. Kannel,W.P. Castelli
Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study
N Engl J Med, 322 (1990), pp. 1561-1566 http://dx.doi.org/10.1056/NEJM199005313222203
D. Levy,R.J. Garrison,D.D. Savage,W.B. Kannel,W.P. Castelli
Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framingham Heart Study
Ann Intern Med, 110 (1989), pp. 101-107
M.L. Muiesan,M. Salvetti,D. Rizzoni,M. Castellano,F. Donato,E. Agabiti-Rosei
Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment
J Hypertens, 13 (1995), pp. 1091-1095
P. Verdecchia,F. Angeli,C. Borgioni,R. Gattobigio,G. de Simone,R.B. Devereux
Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a metaanalysis
Am J Hypertens, 16 (2003), pp. 895-899
P. Verdecchia,G. Schillaci,C. Borgioni,A. Ciucci,R. Gattobigio,I. Zampi
Prognostic Significance of Serial Changes in Left Ventricular Mass in Essential Hypertension
Circulation, 97 (1998), pp. 48-54
P.M. Okin,R.B. Devereux,S. Jern,S.E. Kjeldsen,S. Julius,M.S. Nieminen
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events
R.B. Devereux,K. Wachtell,E. Gerdts,K. Boman,M.S. Nieminen,V. Papademetriou
Prognostic significance of left ventricular mass change during treatment of hypertension
D. Levy,K.M. Anderson,D.D. Savage,W.B. Kannel,J.C. Christiansen,W.P. Castelli
Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study
Ann Intern Med, 108 (1988), pp. 7-13
J. Sundstrom,L. Lind,J. Arnlov,B. Zethelius,B. Andren,H.O. Lithell
Echocardiographic and Electrocardiographic Diagnoses of Left Ventricular Hypertrophy Predict Mortality Independently of Each Other in a Population of Elderly Men
Circulation, 103 (2001), pp. 2346-2351
K. Alfakih,K. Walters,T. Jones,J. Ridgway,A.S. Hall,M. Sivananthan
New gender-specific partition values for ECG criteria of left ventricular hypertrophy: recalibration against cardiac MRI
M. Foppa,B.B. Duncan,L.E. Rohde
Echocardiography-based left ventricular mass estimation. How should we define hypertrophy?
Cardiovasc Ultrasound, 3 (2005), pp. 17 http://dx.doi.org/10.1186/1476-7120-3-17
G.P. Rossi,A. Sacchetto,P. Visentin,C. Canali,G.R. Graniero,P. Palatini
Changes in Left Ventricular Anatomy and Function in Hypertension and Primary Aldosteronism
Hipertensión, 27 (1996), pp. 1039-1045
A. Losito,R.M. Fagugli,I. Zampi,B. Parente,P. de Rango,G. Giordano
Comparison of Target Organ Damage in Renovascular and Essential Hypertension
Am J Hypertens, 9 (1996), pp. 1062-1067
R.E. Schmieder,M.R.W. Langenfeld,A. Friedrich,H.P. Schobel,C.D. Gatzka,H. Weihprecht
Angiotensin II Related to Sodium Excretion Modulates Left Ventricular Structure in Human Essential Hypertension
Circulation, 94 (1996), pp. 1304-1309
A.U. Klingbeil,M. Schneider,P. Martus,F.H. Messerli,R.E. Schmieder
A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension
Am J Med, 115 (2003), pp. 41-46
P.M. Okin,R.B. Devereux,S. Jern,S.E. Kjeldsen,S. Julius,M.S. Nieminen
Regression of Electrocardiographic Left Ventricular Hypertrophy by Losartan Versus Atenolol: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study
M.P. Schneider,A.U. Klingbeil,C. Delles,M. Ludwig,R.E. Kolloch,M. Krekler
Effect of Irbesartan Versus Atenolol on Left Ventricular Mass and Voltage: Results of the Cardio- Vascular Irbesartan Project
Hipertensión, 44 (2004), pp. 61-66
B. Dahlof,R.B. Devereux,S.E. Kjeldsen,S. Julius,D.G. Beevers,U. de Faire
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
Correspondencia: epartment of Nephrology and Hypertension. University Erlangen-Nürnberg. Krankenhausstraβe, 12. 91054 Erlangen. Germany. (R.E. Schmieder roland.schmieder@rzmail.uni-erlangen.de)
Copyright © 2007. Sociedad Española de Hipertension-Liga Española para la Lucha de la Hipertensión Arterial (SEH-LELHA)